sarms puresynmr CARDARINE
High purity
Good research and development team
Excellent promotion team
What is ENDUROBOL (GW-501516)
ENDUROBOL (GW501516 or GSK-516) is a PPARδ receptor agonist that was previously investigated for drug use.
ENDUROBOL is a selective agonist with high affinity and it is very potent. Various studies on this PPAR receptor in lab indicates that it regulates the various proteins that the body uses for energy.
ENDUROBOL can help to reduce and even reverse various problems in men who are obese or that have symptoms of pre-diabetes due to problems with their metabolism. The use of GW-501516 is viable treatment for reducing obesity and various conditions that are linked to it.
How it works
ENDUROBOL is a selective agonist (activator) of the PPARδ receptor. It displays high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPARδ with > 1000 fold selectivity over PPARα and PPARγ.
It activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in human.
Dosages and Suggestion
Recommended maximum dose ENDUROBOL is 10 mg per day but many people use as much as 20 mg per day to burn as much fat as they can in in the 8 week cycle.
SARMS We offer
AICAR |
2627-69-2 |
acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown |
MK2866 |
841205-47-8 |
medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy. |
MK-677 |
15972-10-0 |
A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly |
LGD-4033 |
1165910-22-4 |
pharmacological profile similar to that of enobosarm, Ostarine,MK-2866 |
GW501516 |
317318-70-0 |
For obesity, diabetes, dyslipidemia and cardiovascular disease |
Andarine(S4) |
401900-40-0 |
partial agonist, intended mainly for treatment of benign prostatic hypertrophy |
SR9009 |
1379686-30-2 |
under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice |
SR9011 |
1379686-30-2 |
For obesity, diabetes, dyslipidemia and cardiovascular disease |
RAD140 |
1182367-47-0 |
New generation for gaining mass and cutting edges |
YK11 |
366508-78-3 431579-34-9 |
a SARM and myostatin inhibitor in one |
GHRP-2 |
158861-67-7 |
Growth Hormone Releasing Peptide-2 |
GHRP-6 |
87616-84-0 |
Growth Hormone Releasing Peptide-6 |
TB500 |
107761-42-2 |
Thymosin beta 4 |
SM130,686 |
/ |
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View